Díaz ÁY, Chaviano LG, Obret MI, Fumero GFY, Piloto DI

Language: Spanish
References: 11
Page: 1-14
PDF size: 434.43 Kb.

ABSTRACT

Treatment for glaucoma is aimed at reducing the levels of intraocular pressure. This is the only factor that may be treated so far, and it should be individualized. A case is presented of a male 54-year-old mulatto patient, intellectual, with a history of apparently good health who was diagnosed with glaucoma ten years ago. Trabeculectomy with antimetabolite (mitomycin C) was performed on the patient's left eye in the year 2012 due to advanced glaucomatous damage. In the year 2016 the patient attended our service and reported poor vision and uncontrolled intraocular pressure in both eyes. Very high intraocular pressure values above 30 mmHg were confirmed in both eyes. In the right eye the vision unit with its best correction, and very advanced campimetric damage limited to a central vision island with a fall to 5° central, whereas the left eye did not achieve light perception. After combining 3 drug lines at their maximum dosage, intraocular pressure values were not protective. The dilemma arose whether to perform filtration surgery, fearing the high surgical risk, being as it was a single eye, or not to perform any surgery and just go on with the drug treatment despite not having achieved target intraocular pressure values. It was decided to perform non-penetrating deep sclerectomy with antimetabolite (0.02% mitomycin C). No associated complications occurred and intraocular pressured fell to 24 mmHg. Therefore, goniopuncture was performed one month after surgery. The target intraocular pressure was obtained without glaucomatous damage progression and visual acuity was preserved.

REFERENCES

1. Bauchiero L, Demarie A, Belli L, Brogliatti B. Deep sclerectomy and viscocanalostomy: critical revision of the results obtained during the learning curve. Acta Ophthalmol Scand. 2002 [acceso: 05/07/2007];80(236):64–6. Disponible en: http://www.ingentaconnect.com/mksg/aos/2002/00000080/A236s236/art00047

2. Aguilar E, Reyes S. Glaucoma: la enfermedad silenciosa. Fundación Visión COI; 2006 [acceso: 05/07/2007]. Disponible en: http://www.fundationvisioncoi.es/trabajos%20investigacion%20/5/glaucoma.pdf

3. Lachkar Y, Hamard P. Nonpenetrating filtering surgery. Curr Opin Ophthalmol. 2002;13:110-5.

4. Özsoy A, Sinan M, Çavuşoğlu M. El efecto de la esclerectomía profunda en el flujo sanguíneo ocular: un ensayo clínico de 6 meses. Rev Turca Cienc Méd. 2016;46(6).1773-8.

5. Carassa RG. Surgical alternative to trabeculectomy. Progr Brain Res. 2008 [acceso: 22/12/2008];173:[aprox. 6 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/18929114

6. Karakurt Y, Mesci C, Erbil HH, Salar Gomceli S, Acar H. Comparación de la eficacia clínica y la seguridad de la esclerectomía profunda con mitomicina-C y cirugías de trabeculectomía. An Med Res. 2019;26(2):279-88.

7. Guedes R, Guedes V, Chaoubach A. Factors associated with non-penetrating deep sclerectomy failure in controlling intraocular pressure. Acta Ophthalmol. 2011;89:58-61.

8. Mansouri K, Mariani A, Ravinet E. Reconditioning of the trabeculo-descemet'membrane with the 532-nm Nd: YAG (SLT) laser alter deep sclerectomy. Eye. 2011;25:1655-7.

9. Penaud P, Leleu I, Laplace O, Akesbi J, Blumen-Ohana E, Nordmann JP. Resultados de la goniopuntura láser después de la esclerectomía profunda no penetrante con mitomicina C: un gran estudio de cohorte retrospectivo. J Glauc. 2019;28(1):51-5.

10. Leleu I, Penaud B, Blumen-Ohana E, Rodallec T, Adam R, Laplace O, Akesbi J, Nordmann JP. Evaluación de riesgos de pérdida visual repentina después de la esclerectomía profunda no penetrante en el glaucoma severo y en etapa terminal. Ojo. 2019;33(6):902-9.

11. Leleu I, Penaud B, Blumen-Ohana E, Rodallec T, Adam R, Laplace O, Akesbi J, Nordmann JP. Cambio central del campo visual de 10 grados después de una esclerectomía profunda no penetrante en glaucoma grave y en etapa terminal: resultados preliminares. Arch Graef Oftalmol Clín Experim. 2018;256(8):1489-98.